問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Dermatology

Division of Rheumatology

更新時間：2023-09-19

顏在弘
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

18Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏在弘

List

25Cases

2023-12-26 - 2026-05-14

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2023-10-15 - 2025-06-18

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2023-02-01 - 2024-08-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-06-01 - 2026-06-08

Phase III

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State

  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    injection

Participate Sites
4Sites

Recruiting4Sites

2024-02-12 - 2026-06-01

Phase III

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjogren's Syndrome With Moderate-to-Severe Symptom State

  • Condition/Disease

    Sjogren's Syndrome

  • Test Drug

    Dazodalibep

Participate Sites
5Sites

Recruiting5Sites

2025-09-01 - 2029-12-31

Phase III

Active
A Multicenter, Long-term, Randomized, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS)

  • Condition/Disease

    Sjögren’s Syndrome (SS)

  • Test Drug

    Injection

Participate Sites
5Sites

Recruiting5Sites

2026-06-01 - 2029-01-16

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2024-12-01 - 2027-11-30

Phase III

Active
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ – CSU1)

  • Condition/Disease

    Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ – CSU1)

  • Test Drug

    injection

Participate Sites
10Sites

Recruiting10Sites

2024-09-01 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-12-01 - 2025-12-31

Phase IV

Active
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population

  • Condition/Disease

    Lupus Nephritis

  • Test Drug

    Myfortic 180 mg、360 mg Gastro-Resistant Tablets

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB